EyeGate’s anti-inflammatory eye drug and electric delivery device fail phase 3 trial
EyeGate Pharmaceuticals’ corticosteroid treatment for noninfectious anterior uveitis—delivered directly into the ocular tissue via the company’s device and a low-level…
